Quest Diagnostics Retained Earnings (Accumulated Deficit) 2010-2024 | DGX
Quest Diagnostics retained earnings (accumulated deficit) from 2010 to 2024. Retained earnings (accumulated deficit) can be defined as profits reinvested in the corporation after dividends have been paid out.
- Quest Diagnostics retained earnings (accumulated deficit) for the quarter ending December 31, 2024 were $9.360B, a 6.06% increase year-over-year.
- Quest Diagnostics retained earnings (accumulated deficit) for 2024 were $9.36B, a 6.06% increase from 2023.
- Quest Diagnostics retained earnings (accumulated deficit) for 2023 were $8.825B, a 6.45% increase from 2022.
- Quest Diagnostics retained earnings (accumulated deficit) for 2022 were $8.29B, a 8.38% increase from 2021.
Quest Diagnostics Annual Retained Earnings (Accumulated Deficit)
(Millions of US $) |
| 2024 |
$9,360 |
| 2023 |
$8,825 |
| 2022 |
$8,290 |
| 2021 |
$7,649 |
| 2020 |
$9,303 |
| 2019 |
$8,174 |
| 2018 |
$7,602 |
| 2017 |
$7,138 |
| 2016 |
$6,613 |
| 2015 |
$6,199 |
| 2014 |
$5,723 |
| 2013 |
$5,358 |
| 2012 |
$4,690 |
| 2011 |
$4,264 |
| 2010 |
$3,867 |
| 2009 |
$3,217 |
Quest Diagnostics Quarterly Retained Earnings (Accumulated Deficit)
(Millions of US $) |
| 2024-12-31 |
$9,360 |
| 2024-09-30 |
$9,222 |
| 2024-06-30 |
$9,080 |
| 2024-03-31 |
$8,935 |
| 2023-12-31 |
$8,825 |
| 2023-09-30 |
$8,711 |
| 2023-06-30 |
$8,566 |
| 2023-03-31 |
$8,412 |
| 2022-12-31 |
$8,290 |
| 2022-09-30 |
$8,263 |
| 2022-06-30 |
$8,083 |
| 2022-03-31 |
$7,926 |
| 2021-12-31 |
$7,649 |
| 2021-09-30 |
$7,333 |
| 2021-06-30 |
$10,246 |
| 2021-03-31 |
$9,690 |
| 2020-12-31 |
$9,303 |
| 2020-09-30 |
$8,800 |
| 2020-06-30 |
$8,307 |
| 2020-03-31 |
$8,197 |
| 2019-12-31 |
$8,174 |
| 2019-09-30 |
$7,992 |
| 2019-06-30 |
$7,849 |
| 2019-03-31 |
$7,694 |
| 2018-12-31 |
$7,602 |
| 2018-09-30 |
$7,546 |
| 2018-06-30 |
$7,401 |
| 2018-03-31 |
$7,249 |
| 2017-12-31 |
$7,138 |
| 2017-09-30 |
$6,946 |
| 2017-06-30 |
$6,847 |
| 2017-03-31 |
$6,715 |
| 2016-12-31 |
$6,613 |
| 2016-09-30 |
$6,520 |
| 2016-06-30 |
$6,384 |
| 2016-03-31 |
$6,244 |
| 2015-12-31 |
$6,199 |
| 2015-09-30 |
$6,066 |
| 2015-06-30 |
$5,793 |
| 2015-03-31 |
$5,729 |
| 2014-12-31 |
$5,723 |
| 2014-09-30 |
$5,581 |
| 2014-06-30 |
$5,500 |
| 2014-03-31 |
$5,415 |
| 2013-12-31 |
$5,358 |
| 2013-09-30 |
$5,260 |
| 2013-06-30 |
$4,898 |
| 2013-03-31 |
$4,779 |
| 2012-12-31 |
$4,690 |
| 2012-09-30 |
$4,682 |
| 2012-06-30 |
$4,546 |
| 2012-03-31 |
$4,396 |
| 2011-12-31 |
$4,264 |
| 2011-09-30 |
$4,101 |
| 2011-06-30 |
$3,945 |
| 2011-03-31 |
$3,798 |
| 2010-12-31 |
$3,867 |
| 2010-09-30 |
$3,719 |
| 2010-06-30 |
$3,538 |
| 2010-03-31 |
$3,361 |
| 2009-12-31 |
$3,217 |
| 2009-09-30 |
$3,053 |
| 2009-06-30 |
$2,880 |
| 2009-03-31 |
$2,710 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Outpatient & Home Care |
$19.317B |
$9.872B |
|
Quest Diagnostics, Inc. is the provider of commercial laboratory services. Quest provides lab testing services to physicians, hospitals, managed care organizations, employers, government institutions and other clinical laboratories. The company consists of 2 business groups - Diagnostic Information Services and Diagnostic Solutions. The company's focus is on two elements - to accelerate growth and to drive operational excellence. Restore Growth: The company has adopted seven tactical approaches to accelerate growth such as sales and marketing; development of esoteric testing through a disease focus; partnerships with hospitals and successful testing of international IDNs; creation of value from information assets; leadership in companion diagnostics; extension into adjacent markets. Drive Operational excellence: The company plans to focus on four strategic requirements - to enhance end-to-end customer value chain, enterprise information technology architecture, business performance tools and cost excellence.
|
